Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.
Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.
Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?
Whitehawk Therapeutics unveiled AACR 2026 data for three ADCs. Read what it means for pipeline differentiation, risk, and investor sentiment.
Can Byondis turn novel ADC payload chemistry into a real edge in resistant cancers?
Byondis is showcasing two new ADC technology platforms at AACR 2026. Read why antifolate and phosphonate payloads could reshape oncology innovation.
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.
Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?
Soley Therapeutics unveiled AACR 2026 data for STX-6398. Read why CKAP2 modulation could open a new path in oncology.
Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
How Boehringer Ingelheim and Zai Lab are advancing a two-pronged DLL3 attack in SCLC
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.
Zentalis Pharmaceuticals aligns DENALI and ASPENOVA trials with evolving ovarian cancer treatment landscape
Zentalis Pharmaceuticals advances azenosertib through DENALI and ASPENOVA. Read what this means for ovarian cancer strategy and approval risk.